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VesicleCleavage of Rho associated Coiled Coil kinase I (ROCK I) by caspase-3 contributes to membrane blebbing.
Whether caspase-3 and ROCK I also play a role in the release of membrane vesicles is unknown. Therefore,
we transfected a human breast cancer cell line (MCF-7) that is caspase-3 deﬁcient, lacks membrane blebbing,
and does not release membrane vesicles, with caspase-3. Cells expressing caspase-3 demonstrate both ROCK
I-mediated membrane blebbing, and release of small (400–600 nm) membrane vesicles in a ROCK
I-independent manner. These membrane vesicles contain caspase-3, and are enriched in caspase-3 activity
compared to the releasing cells. Caspase-3-containing vesicles are taken up by untransfected cells but the
cells do not show any sign of apoptosis. In conclusion, we show that the release of caspase-3-enriched mem-
brane vesicles and membrane blebbing are two differentially regulated processes. Furthermore, we hypoth-
esize that packaging of caspase-3 into membrane vesicles contributes to cellular homeostasis by the removal
of caspase-3, and concurrently, protects the cells' environment from direct exposure to caspase-3 activity.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Membrane (extracellular) vesicles (further mentioned as vesi-
cles) are 30–1000 nm in diameter, and such vesicles are ubiquitously
present in conditioned culture media and body ﬂuids including
blood, saliva, liquor cerebrospinalis, and synovial ﬂuid. Vesicles are
present in physiological and pathological circumstances, and their
numbers, cellular origin, composition, and function, are disease
(state) dependent. Vesicles are known for their coagulant phenotype
[8,17,29–31,39,46], but they can also affect inﬂammation [4–7,18,23]
and angiogenesis [10,22,28], and contribute to intercellular signaling
[20,37,40,41].
Vesicles from human blood cells and endothelial cells contain
caspase-3 [2]. Because release of caspase-3-containing vesicles
seems to counteract the induction of apoptosis [15], and because in-
hibition of vesicle release results in the intracellular accumulation of
caspase-3 and apoptosis [1], we and others hypothesize that the re-
lease of such caspase-3-containing vesicles may be a general mecha-
nism that contributes to cellular homeostasis by counteracting
cellular stress [1,14,15].istry, AcademicMedical Center,
el.: +31 20 5665803; fax: +31
l rights reserved.Whether membrane blebbing is a process that results in the re-
lease of vesicles, or whether membrane blebbing and vesicle release
are two independent processes, is unknown. Membrane blebbing,
which is a characteristic feature of cells undergoing apoptosis, can
be induced by activation of Rho associated Coiled Coil kinase I
(ROCK I). ROCK I is activated by either caspase-3-induced cleavage,
or via Rho GTPase. Activated ROCK I induces an increase in myosin
light chain phosphorylation, which in turn contributes to membrane
blebbing [12,34].
Although caspase-3 induces membrane blebbing by cleavage of
ROCK I [12,34], and vesicles contain caspase-3, it is unknownwhether
caspase-3 plays any role in vesicle release, whether vesicle release is
mediated by ROCK I, and whether vesicles are enriched in caspase-3
activity compared to the cells. To address these questions, we used
a human breast cancer cell line MCF-7, which lacks membrane bleb-
bing and is deﬁcient of caspase-3, to study the role of caspase-3 and
ROCK I in the release of vesicles.2. Material and methods
2.1. Human caspase-3 expression vectors
Twenty nine kDa caspase-3 was cloned untagged (caspase-3) or
tagged with the EGFP sequence at the 3′end (caspase-3*). Twenty nine
1845A.N. Böing et al. / Biochimica et Biophysica Acta 1833 (2013) 1844–1852kDa caspase-3 is known to activate itself by autocleavage, resulting in
17 kDa and 12 kDa caspase-3 fragments [27].
For cloning details please see supplementary data.
2.2. Transfection of MCF-7 cells
MCF-7 cells were a gift from the Hubrecht Laboratory (Utrecht,
The Netherlands). MCF-7 cells were selected since they lack the
procaspase-3 protein due to a 125 bp deletion in exon 3 of the
caspase-3 gene. This deletion leads to a frameshift starting at codon
18which results in a stop codon at codon 41 [21]. Cells were cultured
in DMEM F12 (Invitrogen, Carlsbad, CA) supplemented with 7.5%
fetal calf serum (FCS; PAA, Pasching, Austria), non-essential amino
acids (Invitrogen), penicillin and streptomycin (10 units/mL and
10 μg/mL, respectively; Invitrogen) for 2 days before transfection.
Transfection was performed with 1 μg DNA encoding caspase-3,
caspase-3* or EGFP, using Fugene-6 (3 μL; Roche,Mannheim,Germany)
according to the manufacturer's instructions. In all experiments
untransfected cells were used as control unless stated otherwise.
2.3. Release of vesicles and membrane blebbing from caspase-3-
expressing cells by live cell imaging
To visualize the release of vesicles and membrane blebbing, live cell
imaging was performed as described previously [38]. MCF-7 cells
(15,000) were plated in glass-bottom dishes (Lab-Tek II chambered
coverglass; Nunc, Roskilde, Denmark). Cells were incubated for 2 days
at 37 °C in an atmosphere containing 5% CO2. Thereafter, cells were
transfected with the expression construct encoding the caspase-3* pro-
tein. In parallel experiments, cells were either transfected with EGFP or
not transfected. Transfection with caspase-3 (without EGFP) was not
performed because expression of this construct cannot be monitored.
After transfection (4 h), the conditioned culture mediumwas cov-
ered with mineral oil (M3516; Sigma, St. Louis, MO) to prevent evap-
oration of the medium. The glass-bottom dish was placed under an
inverted ﬂuorescence DM IRBE microscope (Leica Microsystems,
Wetzlar, Germany), equipped with a Plan Apo 63×/1.40 oil objective
and a cooled CCD camera (type 2000s; PCO AG, Kelheim, Germany).
Cells were imaged for 48 h at 37 °C in an atmosphere containing 5%
CO2. Phase contrast images were acquired at time intervals of 5 min
and ﬂuorescence images at time intervals of 60 min to monitor ex-
pression of caspase-3*. Live cell images were analyzed using
custom-made software. In the live cell images, vesicles were tran-
siently visible as little black dots near the cell membrane.
2.4. Detailed visualization of the release of vesicles by live cell imaging
MCF-7 cells were cultured in glass-bottom dishes as described
above, and subsequently transfected with the expression vector
encoding the caspase-3* protein. After transfection for 24 h, the con-
ditioned culture medium was covered with mineral oil and cells were
imaged for 5 h. A phase contrast image was made every 5 or 20 s,
depending on the experiment. Fluorescence images were made only
at the start of the experiment to monitor expression of caspase-3*
to circumvent the risk of apoptosis from phototoxicity. Live cell im-
ages were analyzed using custom-made software and vesicles were
visible as moving little black dots.
2.5. Quantiﬁcation of vesicles released from caspase-3-expressing cells
2.5.1. Isolation of vesicles from cell-conditioned culture supernatant
MCF-7 cells (45,000) were cultured in 6-well plates and transfected
as described. At 48 h after transfection, culture supernatants were
harvested and centrifuged for 10 min at 180 g to remove detached
cells. Vesicleswere isolated fromcell-free supernatant by centrifugation
at 18,890 g. Vesicles were washed once and used for the various assays.2.5.2. Flow cytometry of vesicles
To estimate the number of released vesicles, the vesicles were isolat-
ed from cell-free culture supernatant (250 μL) by centrifugation (30 min
at 18,890 g). After centrifugation, vesicle-free supernatant was removed
(225 μL) and vesicles were resuspended in PBS-containing citrate 0.32%
(225 μL) to avoid clumping. After washing at 18,890 g for 30 min,
vesicle-free supernatant was removed (225 μL) and vesicles were
resuspended in the remaining ﬂuid. Thereafter, vesicles (5 μL) were
added to a mixture of PBS-containing 2.5 mmol/L calcium chloride
(35 μL) and allophycocyanin (APC)-labeled annexin V (5 μL; Caltag
Medsystems, Buckingham, UK) and were incubated for 15 min at room
temperature. Thereafter, PBS-containing calcium chloride (300 μL) was
added and vesicles were counted on a FACSCalibur (Becton Dickinson,
San Jose, CA) for 1 min and analyzedwith CellQuest™ pro software (ver-
sion 4.02; Becton Dickinson). To estimate the number of released vesi-
cles, we measured the ﬂow rate in μL/min for each experiment and
used the following formula: numbers of vesicles/well = counted num-
bers annexin V-positive vesicles × (350 μL/ﬂow rate in μL per
min) × (25 μL/5 μL) × (2000 μL culture medium per well/250 μL).2.5.3. Resistive pulse sensing
MCF-7 cells (45,000) were cultured in 6-well plates and transfected
as described. At 48 h after transfection, culture supernatants were
harvested and centrifuged for 10 min at 180 g to remove detached
cells. The concentration and size distribution of vesicles were
measured with resistive pulse sensing (qNano; Izon, Christchurch,
New Zealand) using a NP200A nanopore and a NP400A nanopore.
Samples were measured with a pressure of 7 mbar, stretch of
45.00 mm, and voltage of 0.40 V. Samples were analyzed for 10 min
or until 1000 vesicles were counted. Results obtained with the
NP200A pore were used for vesicles with a diameter of less than
400 nm (the NP200A pore is optimized for the detection of vesicles of
100 nm–400 nm and the NP400A pore is optimized for the detection
of vesicles of 200–800 nm; personal communication with Izon).
Results obtained with the NP400A pore were used for vesicles with a
diameter of 400 nm to 1000 nm. The concentration of vesicles present
in the culture supernatant of untransfected cells was subtracted from
the concentration of vesicles present after transfection with EGFP,
caspase-3 or caspase-3*.2.6. Inhibition of vesicle release
To investigate whether the release of vesicles is ROCK I mediated,
we transfected MCF-7 cells as described in the presence or absence of
the ROCK I inhibitor Y27632 (30 μM in PBS, 2 h preincubation; Tocris,
Ellisville, MO) and analyzed the number of generated vesicles by ﬂow
cytometry and resistive pulse sensing as described before.2.7. Detection of intravesicular active caspase-3
For detection of intravesicular active caspase-3, vesicles were isolat-
ed from cell-free culture supernatant (250 μL) by centrifugation
(30 min 18,890 g). After centrifugation, vesicle-free supernatant was
removed (225 μL) and vesicles were washed in 0.1% permwash
(225 μL; Becton Dickinson) by centrifugation at 18,890 g for 30 min.
Then, the vesicle-free supernatant was removed and vesicles were
resuspended in the remaining ﬂuid. Vesicles (5 μL) were added to a
mixture of permwash-containing 2.5 mmol/L calcium chloride
(35 μL), APC-labeled annexin V (5 μL) and phycoerythrin (PE)-labeled
anti-caspase-3 (recognizes only the active form of caspase-3; Becton
Dickinson), and incubated for 30 min at room temperature. After incu-
bation, permwash (300 μL)-containing 2.5 mmol/L calcium chloride
was added and samples were analyzed on a FACSCalibur for 1 min.
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To measure intracellular caspase-3 activity, MCF-7 cells were
transfected as described, and after 48 h, cells were harvested after
trypsinization and washed (10 min and 180 g) using PBS containing
1% FCS. Then, cells (600,000) were washed with PBS and lysed in cell
lysis buffer (Calbiochem, San Diego, CA; 60 μL) for 5 min at 4 °C be-
fore 3 freeze/thaw cycles in liquid nitrogen and at 37 °C, respective-
ly. Then, lysates were centrifuged for 10 min at 10,000 g and
supernatants were used to measure caspase-3 activity. Caspase-3
activity was determined by using the chromogenic substrate
Ac-DEVD-pNA (Calbiochem) in the presence or absence of the
caspase-3 inhibitor Ac-DEVD-CHO (Calbiochem). The absorbance at
405 nm was measured during 90 min with time intervals of 5 min,
as developed by Barrett and Cathepsin [3] and Du et al. [16], and as
described by the manufacturer. To calculate the caspase-3 activity
in the samples, a conversion factor of the plate reader was used.
The conversion factor was determined by measuring the absorbance
of 50 μM ρ-nitroaniline at 405 nm, and calculated as ratio of the con-
centration of ρ-nitroaniline and absorbance. To calculate the
caspase-3 activity in samples in pmol/min, ﬁrst the absorbance gen-
erated in time in the presence of Ac-DEVD-CHO was subtracted from
the absorbance generated in its absence. Second, the net increase in
absorbance was divided by the measuring time (90 min). Thereafter,
the formula described by the manufacturer was used: net increase in
absorbance/min × conversion factor × assay volume (μL). The
caspase-3 activity in pmol/min was expressed per μg protein as de-
termined by the Coomassie brilliant blue assay (Pierce, Rockford, IL).
To measure intravesicular caspase-3 activity, 2 × 1 mL cell-free
culture supernatant was centrifuged for 1 h at 18,890 g. Vesicles
were pooled and washed once in 1 mL PBS. Thereafter, 990 μL super-
natant was removed and vesicles were resuspended in 50 μL cell lysis
buffer followed by measurement of caspase-3 activity using the same
procedure as described for cells.
2.9. Western blot
Vesicles were isolated from 2 × 1 mL cell-free culture superna-
tant by centrifugation at 18,890 g for 1 h, pooled and washed once
in PBS. Then vesicles were resuspended in 25 μL reducing sample
buffer. All samples were boiled for 5 min. Samples (15 μL) were
loaded on an 8–16% gradient gel (Biorad, Hercules, CA) and blotted
to polyvinylidene diﬂuoride (PVDF) membrane (Millipore, Billerica,
MA). Membranes were incubated with 5% protifar (Nutricia, Vienna,
Austria) in Tris-buffered saline with 0.005% Tween (Merck, Darmstadt,
Germany) for 1 h to reduce non-speciﬁc staining, followed by incubation
with a mouse anti-human caspase-3 antibody (clone 31A1067 recog-
nizing 29 kDa- and 17 kDa caspase-3; Alexis, San Diego, CA) or a mouse
anti-human-GFP-horseradish peroxidase-labeled antibody (Miltenyi
Biotec, Bergisch Gladbach, Germany). For blots incubated with
caspase-3 antibody, a secondary antibody goat anti-mouse-horseradish
peroxidase (1:30,000; Dako, Glostrup, Denmark) was used. To visualize
the bands, membranes were incubated with a 5-fold diluted peroxidase
substrate (LumiLight; Roche Diagnostics, Almere, The Netherlands) for
5 min, followed by analysis of luminescence using a LAS3000 lumines-
cence image analyzer (Fuji, Valhalla, NY).
2.10. Transfer of caspase-3 to MCF-7 cells by vesicles
MCF-7 cells were cultured and transfected as described, except for
the removal of the transfection medium after 5 h of transfection and
washing the cells once with PBS before addition of fresh culture medi-
um to ensure that the fugene/DNA mixture was completely removed.
After 42 h, the conditioned culture supernatant was harvested and de-
tached cells were removed by centrifugation (180 g 10 min, 4 °C). Ves-
icles (5 aliquots of 1 mL) were isolated from cell-free culturesupernatant by centrifugation (18,890 g, 1 h, 4 °C). Vesicle-free super-
natant (975 μL) was removed and used as control. Vesicle pellets
were resuspended in the remaining 25 μL. Vesicles of one pellet were
used directly and the other vesicle-pellets (4 × 25 μL) were pooled
and concentrated to 25 μL by centrifugation (18,890 g, 30 min, 4 °C).
Two days before addition of vesicles, MCF-7 cells were cultured in a
12-well plate. Before addition of vesicles, culture mediumwas replaced
by fresh culture medium and thereafter, the indicated vesicle-free su-
pernatants (25 μL), or vesicles (25 μL)were added. After 48 h, adherent
cells and detached cells were harvested. Cell numbers were counted
and EGFP ﬂuorescence was measured using a FACSCalibur (Becton
Dickinson). Cells were labeled with annexin V-APC and propidium io-
dide (Invitrogen) as described before [1]. Cells were also labeled with
anti-caspase-3-PE (Becton Dickinson) as described before [1].
2.11. Statistical analysis
All data were analyzedwith GraphPad Prism forWindows, release 5
(Prism, San Diego, CA). Data from all experiments were analyzed with
unpaired t tests (one tailed) and values are expressed as mean ± SD.
3. Results
3.1. No release of vesicles from untransfected MCF-7 cells
MCF-7 cells are caspase-3 deﬁcient and lack membrane blebbing.
Whether this deﬁciency of caspase-3 impairs the release of vesicles
is unknown. Therefore, we determined whether untransfected
MCF-7 cells release vesicles. As shown in Fig. 1A, such cells hardly re-
lease any vesicles. Furthermore, MCF-7 cells do not show the typical
morphological features of cells undergoing apoptosis, such as cell
shrinkage or membrane blebbing (live cell imaging, data not shown).
3.2. Release of vesicles from caspase-3-expressing MCF-7 cells
After transfection, MCF-7 cells express both caspase-3 and caspase-
3-EGFP (caspase-3*). Both forms of caspase-3 show autocleavage
resulting in the characteristic 17 kDa and 12 kDa/12 kDa-EGFP frag-
ments (data not shown). The release of vesicles increases approxi-
mately 5-fold and 3-fold, respectively, in cells expressing either
caspase-3 or caspase-3* compared to control (EGFP-expressing)
cells (Fig. 1A; P = 0.005 and P = 0.003, respectively).
Because ﬂow cytometry (Fig. 1A) underestimates the concentration
of vesicles and gives hardly any information about their size and size
distribution [42,43], we also analyzed the vesicles using resistive pulse
sensing in an independent series of experiments. Fig. 1B conﬁrms that
the release of vesicles increases when cells express either caspase-3 or
caspase-3*. This increase is signiﬁcant for relatively large vesicles with
a diameter between 400–500 and 500–600 nm released from cells ex-
pressing caspase-3* as compared to these sizes of vesicles released
from control (EGFP) cells (P = 0.019 and P = 0.008, respectively),
but not signiﬁcant for vesicles with a diameter between 100–200 and
200–300 nm (P = 0.4041 and P = 0.0617, respectively). Taken to-
gether, the release of relatively large membrane vesicles by MCF-7
cells increases when the cells express caspase-3.
To visualize the release of the vesicles, live cell imaging experi-
ments were performed with MCF-7 cells expressing caspase-3*. In
the ﬁrst experiments, we made phase contrast images every 5 min.
In this ﬁlm, the released vesicles are visible as little black dots
(Suppl. ﬁlm). To obtain a more detailed insight into the release of ves-
icles, we also performed experiments where images were made every
5 or 20 s of cells expressing caspase-3*. Fig. 1C–F and G–I show the
release of single vesicles from 2 different cells. In Fig. 1C–F, a phase
contrast image was made every 20 s, showing the formation of a ves-
icle within a membrane rufﬂe (C), the vesicle just before release (D),
the release of the vesicle (E) and the released vesicle (F). In Fig. 1G–I,
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Fig. 1. Release of vesicles from MCF-7 cells expressing caspase-3. A. The number of vesicles released from caspase-3-expressing- and caspase-3-EGFP (caspase-3*)-expressing
MCF-7 cells (n = 5 and n = 6, respectively) was determined by annexin V ﬂuorescence using ﬂow cytometry. Untransfected (n = 4) and EGFP-transfected cells (n = 8) were
used as controls. B. The concentration of particles released from MCF-7 cells expressing caspase-3 or caspase-3* (n = 4) was determined by resistive pulse sensing. Untransfected
(n = 4) and EGFP-transfected cells (n = 4) were used as controls. C–I. Vesicle release (arrows) from caspase-3*-expressing cells (C–F and G–I) was visualized and studied with live
cell imaging. A phase contrast image was made every 20 s (C–F) or every 5 s (G–I). C. A vesicle is formed in a membrane rufﬂe. D. The vesicle is almost released from the membrane.
E. Release of the vesicle. F. The released vesicle has moved out of focus. G. A vesicle is formed at the cell membrane. H. Release of the vesicle. I. The vesicle is released.
1847A.N. Böing et al. / Biochimica et Biophysica Acta 1833 (2013) 1844–1852a phase contrast image was made every 5 s, showing a vesicle at the
cell membrane (G), the release of the vesicle (H) and the released
vesicle (I). These live cell images also show that cells releasing the
vesicles do not yet show the characteristic morphological features of
apoptosis, including cell shrinkage and membrane blebbing.3.3. No involvement of ROCK I in vesicle release
When MCF-7 cells express caspase-3, they show the characteristic
membrane blebbing, which is absent when the cells are pre-treated
with an inhibitor of ROCK I. Thus, also in our model the caspase-
3-induced membrane blebbing strictly depends on activation of ROCK I
(see Suppl. Fig. 1) [12,34]. In contrast, the release of vesicles is unaffectedby inhibition of ROCK I (Fig. 2), showing that membrane blebbing and
the release of vesicles are 2 different processes.
Then the question was raised whether the active form of caspase-3
was required for the release of vesicles. To address this question, we
preincubated cells expressing caspase-3* with the caspase-3 inhibitor
Z-DEVD-FMK, and we observed an approximately 70% reduction in
the release of vesicles (data not shown), strongly indicating that
caspase-3 activity is required for the release of vesicles.
3.4. Vesicles contain caspase-3
Previously, we and others have shown that vesicles contain
caspase-3 or a caspase-3-like activity [1,2,9,14,15]. Because caspase-3
induces the release of vesicles (this study), we hypothesized that cells
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Fig. 2. No involvement of ROCK I in vesicle release. A. The number of vesicles released from caspase-3-expressing- and caspase-3*-expressing MCF-7 cells in the absence or presence
of the ROCK I inhibitor Y27632 (n = 3) was determined by annexin V ﬂuorescence using ﬂow cytometry. Untransfected (n = 3) and EGFP-transfected cells (n = 3) were used as
controls. B–D. The concentration of particles released by caspase-3-expressing (C, n = 4) and caspase-3*-expressing MCF-7 cells (D, n = 4) in the absence or presence of the ROCK
I inhibitor Y27632 was determined by resistive pulse sensing. Untransfected (n = 4) and EGFP-transfected cells (B, n = 4) were used as controls.
1848 A.N. Böing et al. / Biochimica et Biophysica Acta 1833 (2013) 1844–1852may try to escape from caspase-3-induced cell death by sorting
caspase-3 into vesicles, which are then released.
The presence of caspase-3 was conﬁrmed by Western blot
(Fig. 3A). Vesicles contain the 17 kDa cleavage product of caspase-3,
and vesicles from cells expressing caspase-3* also contain detectable
quantities of the 12 kDa-EGFP cleavage product (40 kDa; anti-GFP
blot) and uncleaved caspase-3*(57 kDa; both anti-caspase-3 blot
and anti-GFP blot). Western blots do not provide any information
on the presence of caspase-3 in single vesicles, and therefore, we
also used ﬂow cytometry. On average, caspase-3 is detectable in 55%
and 51% of the vesicles from cells expressing caspase-3 or
caspase-3*, as compared to 3% and 11% of vesicles from untransfected
cells or EGFP-expressing cells, respectively (Fig. 3B).
Vesicles from cells expressing caspase-3 or caspase-3* contain the
active (17 kDa) form of caspase-3, and thus we measured caspase-3
activity in both vesicles and the corresponding cells. Vesicles from
cells expressing caspase-3 or caspase-3* contain 9 to 10-fold higher
caspase-3 activity than the corresponding cells (Fig. 4; P = 0.009
and P = 0.0004, respectively), and caspase-3 activity was low or ab-
sent in control cells and vesicles. Thus, vesicles are enriched in
caspase-3 activity compared to cells, revealing that active caspase-3
is indeed sorted into vesicles.
3.5. Transfer of caspase-3 to MCF-7 cells by vesicles
It is tempting to compare caspase-3-enriched vesicles to small
cargo containers which contain waste. The obvious question then is,are such waste-containing containers harmful to their environment?
To address this issue, we incubated untransfected MCF-7 cells with
vesicles, isolated from different volumes (i.e. 1 and 4 mL) of condi-
tioned culture medium containing vesicles from cells transfected
with caspase-3(*). Within 48 h, approx. 60% of the added vesicles
disappeared from the culture medium in the presence of target
cells, whereas approx. 30% of the vesicles disappeared in the absence
of target cells (data not shown). Thus, we assume that the net disap-
pearance of approx. 30% of the vesicles was due to their uptake by
cells.
After uptake of vesicles by untransfected cells, fractions of MCF-7
cells were positive for EGFP (Fig. 5A). Also minute fractions of cells
stained for caspase-3 (Fig. 5B), and even smaller fractions of cells
showed signs of early apoptosis (annexin V; Fig. 5C), or detachment
(Fig. 5D). Thus, caspase-3-containing vesicles did bind to or fused
with cells, but that did not lead to a marked increase in apoptosis of
the untransfected cells, showing that the packaging and removal of
caspase-3 by vesicles seem an efﬁcient and safe way to protect both
the releasing cells and the environment from active caspase-3.
4. Discussion
Our present ﬁndings are summarized in a model shown in Fig. 6.
We show that (untransfected) MCF-7 cells, which lack caspase-3
and do not show membrane blebbing, release hardly any vesicles
(Fig. 6A, top). When cells express caspase-3, the cells release vesicles
(Fig. 6B, left) and show (from left to right) different stages of cell
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Fig. 3. Presence of active caspase-3 in vesicles. A. The presence of active caspase-3 in vesicles released fromuntransfected cells, EGFP-, caspase-3- or caspase-3*-expressing cellswas determined
byWestern blot. Blots were incubatedwith anti-caspase-3 or anti-GFP. B. Active caspase-3 in individual vesicles released from untransfected cells (n = 5), EGFP- (n = 5), caspase-3- (n = 5)
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1849A.N. Böing et al. / Biochimica et Biophysica Acta 1833 (2013) 1844–1852shrinkage (rounded cells), membrane blebbing, release of apoptotic
bodies, cell fragmentation, and cell detachment. In the presence of a
ROCK I inhibitor, membrane blebbing is absent in cells expressing
caspase-3, which conﬁrms ﬁndings in earlier studies [12,34]. Howev-
er, the release of vesicles is not inhibited and thus independent of ac-
tivation of ROCK I (Fig. 6C, left). These results show that release of
membrane vesicles and membrane blebbing are 2 processes that are
differentially regulated. Furthermore, we also observed that in the
presence of an inhibitor of ROCK I, cells expressing caspase-3 still
show cell shrinkage, release of apoptotic bodies, cell fragmentation,
and cell detachment (Fig. 6C, from left to right).
Membrane blebbing and the release of vesicles are poorly deﬁned
processes, and it is unknown whether membrane blebbing precedes
or is a prerequisite for formation and release of vesicles. Althoughuntransf.
cells vesicles cells vesicles cells vesicles cells vesicles
0
5
10
15
EGFP caspase-3 caspase-3*
P=0.220 P=0.0479
P=0.009
P=0.0004
Ca
sp
as
e-
3 
ac
tiv
ity
 (p
mo
l.m
in-
1 .
µg
 p
ro
te
in
-
1 )
Fig. 4. Enrichment of active caspase-3 in vesicles. Caspase-3 activity was determined
in untransfected cells (untransf. n = 3), EGFP- (n = 5), caspase-3 (n = 4) and
caspase-3*-expressing cells (n = 5) and their vesicles and was expressed as
pmol·min−1·μg protein−1.membrane blebbing resembles vesicle formation, both processes
may be independent. In our study, it is shown that the release of ves-
icles is not preceded by membrane blebbing (Suppl. ﬁlm and Fig. 1C–
I). Vesicles are released from the cell during membrane rufﬂing, but in
the absence of membrane blebbing. Furthermore, we also show that
membrane blebbing is not a prerequisite for the release of vesicles,
since inhibition of membrane blebbing by inhibition of ROCK I
(shown in Suppl. Fig. 1C) does not interfere with the release of vesi-
cles (Suppl. Fig. 1D and 2). Therefore, we suggest that membrane
blebbing and the release of vesicles are 2 distinct and perhaps even
independent processes.
To exclude the possibility that our results depend on an over-
expression system, we also studied the release of vesicles from a
caspase-3-containing cell line, the human pancreatic adenocarcinoma
BxPC3. Similar to the MCF-7 model, the release of vesicles from BxPC3
cells was unaffected by Y27632, the inhibitor of ROCK I, thus showing
that also in cells expressing normal levels of caspase-3, the inhibition
of ROCK I is unable to prevent the release of vesicles. The release of ves-
icles from BxPC3 cells is inhibited by an inhibitor of caspase-3 activity,
ZDEVD-FMK, showing that caspase-3 activity is necessary for vesicle
formation (data not shown). Thus, the release of vesicles depends on
caspase-3 activity but is independent of ROCK I in both types of cancer
cells.
Previously, we have shown that control, interleukin-1α-stimulated
as well as staurosporin-treated human umbilical vein endothelial cells
(HUVEC) release caspase-3-containing vesicles, which were present
after 3 h when a marker of early apoptosis, i.e. the binding of annexin
V to cells, was virtually absent [1]. Thus, vesicles are released before
the onset of apoptosis, and thus release of vesicles precedes and/or oc-
curs during apoptosis rather than vesicles being formed by membrane
blebbing in the ﬁnal stage of apoptosis. This observation is conﬁrmed
by the data shown in the Suppl. ﬁlm and Fig. 1C–G, in which we show
that vesicles are released in the absence of membrane blebbing.
In the previous endothelial cell study, we also showed that
caspase-3 accumulates in cells when the release of vesicles is inhibited
by combined inhibition of ROCK I and calpain [1]. The knowledge gained
from our recent study provides an alternative explanation of our earlier
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Fig. 5. Transfer of caspase-3 to MCF-7 cells by vesicles. The effect of caspase-3-enriched vesicles on MCF-7 cells was studied by addition of vesicles released from untransfected-
(untransf.), EGFP-, caspase-3 (casp.-3)-, and caspase-3*(casp.-3*)-expressing cells to MCF-7 cells. Two increasing concentrations of vesicles, isolated from 1 mL and 4 mL culture
supernatant, respectively, were used. In all ﬁgures shown, vesicle-free supernatant was used as negative control and subtracted from the signal obtained by vesicles isolated
from 1 mL or 4 mL. A. EGFP positivity in adherent cells was studied and expressed as percentage of total adherent cells. B. Caspase-3 positivity in cells was studied and expressed
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1850 A.N. Böing et al. / Biochimica et Biophysica Acta 1833 (2013) 1844–1852results, assuming that the molecular mechanism underlying the re-
lease of vesicles is conserved. Since we now know that ROCK I is
not involved in the release of vesicles, at least not in MCF-7 cells ex-
pressing caspase-3 and in BxPC3 cells, we may only conclude from
our earlier experiments that the intracellular accumulation of
caspase-3 is hardly dependent on inhibition of ROCK I. Whether the
observed intracellular accumulation of caspase-3 is explained by in-
hibition of calpain alone, however, is unclear, because inhibition of
ROCK I in combination with inhibition of calpain may have an addi-
tional effect than inhibition of calpain alone.
In contrast to our studies, Li et al. reported a ROCK I-mediated ves-
icle release [26]. There may be several explanations for differences in
outcome of our study and that of Li et al. [26], such as the use of dif-
ferent cell types and the fact that Li et al. [26] do not provide evidence
that the release of vesicles is inhibited by the ROCK inhibitor, but
merely show that lower amounts of transglutaminase and ﬂotillin
are present in the isolated vesicles after inhibition of ROCK I. From
other studies, we know that components affecting the biochemical
composition of cell membranes, may also affect the content of vesi-
cles. For example, the intravesicular amount of caspase-3 increased
when the cholesterol-lowering component simvastatin was used,
compared to vesicles released from control cells [15]. Furthermore,
Li et al. [26] show images of blebs at the cell surface, but do not
show that these blebs/vesicles are released. In addition, it is demon-
strated that blebbing is inhibited by a ROCK I inhibitor, as shownpreviously [12,34], a phenomenon which we also observed in our
present study. For their Western blots, Li et al. [26] ﬁrst removed
cell debris at 12.000 g, followed by isolation of the vesicles at
100,000 g, a condition which isolates also smaller vesicles such as
exosomes. It is unknown whether the (released) blebs/vesicles,
which are shown in their images, are removed in the ﬁrst centrifuga-
tion step. Therefore, it is unclear whether the vesicles shown in their
images, or the vesicles isolated by ultracentrifugation are responsible
for the lower amounts of transglutaminase and ﬂotillin.
The molecular mechanisms underlying vesicle release have only
been partially elucidated. For example, platelet-derived vesicles are
released when the actin cytoskeleton becomes destabilized [11], re-
quiring the involvement of phosphoinositide 3-kinase [45]. Also
calpain plays a role because inhibition of calpain blocks the release
of vesicles [13,35]. In addition, ROCK II is involved in the release of
vesicles from endothelial cells [33]. However, to which extent these
mechanisms play any role in the release of vesicles in our model has
to be investigated.
We show that the vesicles are enriched in active caspase-3 com-
pared to the releasing cells. Because addition of such vesicles to
untransfected MCF-7 does not induce apoptosis, caspase-3 that has
been sorted into vesicles does not seem to be harmful to neighboring
cells, at least in vitro. Caspase-3 is not the only protein that is selectively
sorted into vesicles. Well-known examples of sorting of dangerous pro-
teins and other harmfulmolecules into vesicles are e.g. the complement
A) MCF-7 cells untransfected
B) MCF-7 cells expressing caspase-3
cell fragmentation; vesicle release
apoptotic bodies
1 3
detached cell
2 4
membrane blebbing
C) MCF-7 cells expressing caspase-3 in the presence of ROCK I inhibitor
1
2
Fig. 6. Model of vesicle release, membrane blebbing and cell fragmentation of MCF-7 cells. This ﬁgure summarizes our results. A. Untransfected cells hardly release any vesicles. Cell
shrinkage,membrane blebbing and cell fragmentation are absent. B. MCF-7 cells expressing caspase-3 releasemore vesicles than untransfected cells (left), show cell shrinkage (indicated
by the rounded cell), which is followed bymembrane blebbing. This membrane blebbing can (1) directly lead to the release of apoptotic bodies and cell fragmentation (in approximately
50% of the caspase-3* -expressing cells), or (2) result in the retraction ofmembrane blebbing, which can be followed by (3) release of apoptotic bodies and cell fragmentation (in approx-
imately 20% of the caspase-3* -expressing cells) or (4) detachment of the cell (in approximately 30% of the caspase-3* -expressing cells). C. In the presence of the ROCK I inhibitor Y27632,
cells expressing caspase-3 release vesicles and show cell shrinkage, but lack membrane blebbing. Although no membrane blebbing is observed, the rounded cell (1) releases apoptotic
bodies and fragments, or (2) detaches directly without the release of either apoptotic bodies or cell fragments.
1851A.N. Böing et al. / Biochimica et Biophysica Acta 1833 (2013) 1844–1852C5b-9 complex [19], cytostatics [32,36], the proapoptotic ceramide and
prostate apoptosis response 4 [44].We and others suggest that cells use
vesicles to remove dangerous or potentially dangerous molecules that
may threaten the cells' viability and survival. By efﬁcient packaging of
such molecules into vesicles, the cells can remain healthy and viable
[1,14,19,32,36]. In this manner, vesicles contribute to cellular homeo-
stasis by functioning as garbage bags which can then be phagocytosed
and degraded by other cells.
In the present study, we demonstrate that the release of vesicles
and membrane blebbing are 2 different and perhaps even indepen-
dent processes. Furthermore, we show that active caspase-3 is
enriched in vesicles and is not harmful to neighboring cells. We pro-
pose that the sorting of active caspase-3 into vesicles contributes to
cellular defense against apoptosis.
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Appendix A. Supplementary data
The caspase-3 open reading frame was ampliﬁed from the
preprocaspase-3 clone IOH11204 (Invitrogen) using a 5′primerGGGGACAAGTTTGTACAAAAAAGCAGGCTCCACCATGTCTGGAATATC
CCTGGACAAC, and either a 3′primer GGGGACCACTTTGTACAAGA
AAGCTGGGTTCTAGTGATAAAAATAGAGTTCTTTTGT (with stop
codon) or GGGGACCACTTTGTACAAGAAAGCTGGGTTGTAGTGATAAA
AATAGAGTTCTTTTGT (without stop codon). Using Gateway technology
(Invitrogen) [24,25], the resulting PCR fragments were shuttled via
pDON/Zeo (Invitrogen), into pEGFP-N3 (Clontech, Mountain View,
CA). The resulting transfection vectors express the caspase-3 pro-
tein, or the caspase-3-protein tagged with EGFP at the C-terminus
(caspase-3*) under control of the CMV promoter. Supplementary
data to this article can be found online at http://dx.doi.org/10.
1016/j.bbamcr.2013.03.013.References
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